703 results on '"Riedel, Richard"'
Search Results
152. High Data-Rate Neutron-Sensitive Pixelated Detector Using Silicon Photomultiplier
153. Faculty Opinions recommendation of Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma.
154. Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma
155. Faculty Opinions recommendation of The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas.
156. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
157. EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.
158. ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.
159. A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.
160. Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.
161. Acquired resistance to MET inhibition in MET driven NSCLC.
162. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.
163. Faculty Opinions recommendation of Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
164. Assessing the Impact of a Novel Integrated Palliative Care and Medical Oncology Inpatient Service on Health Care Utilization before Hospice Enrollment
165. Monitoring Treatment Response to Erlotinib in EGFR-mutated Non–small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET
166. Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration
167. DEMAND, a Dimensional Extreme Magnetic Neutron Diffractometer at the High Flux Isotope Reactor
168. Sorafenib for Advanced and Refractory Desmoid Tumors
169. Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas
170. Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC
171. Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review
172. Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant
173. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
174. Targeting structural RET and MET kinase alterations in lung adenocarcinoma patients
175. Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC
176. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
177. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
178. Mandibular arch length increase during the mixed dentition: Postretention evaluation of stability and relapse
179. Lung
180. Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology.
181. Faculty Opinions recommendation of Cancer statistics, 2018.
182. Faculty Opinions recommendation of Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
183. Faculty Opinions recommendation of Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
184. Faculty Opinions recommendation of Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine.
185. Faculty Opinions recommendation of Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
186. Faculty Opinions recommendation of Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
187. Faculty Opinions recommendation of Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
188. Faculty Opinions recommendation of Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma.
189. Faculty Opinions recommendation of A precision therapy against cancers driven by KIT/PDGFRA mutations.
190. Faculty Opinions recommendation of Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
191. Faculty Opinions recommendation of Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
192. Faculty Opinions recommendation of Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
193. Faculty Opinions recommendation of Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
194. Faculty Opinions recommendation of Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial.
195. Faculty Opinions recommendation of Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
196. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
197. The experiences of older caregivers of cancer patients following hospital discharge
198. Abstract 1920: Targeting structural RET and MET kinase alterations in lung adenocarcinoma patients
199. A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.
200. SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.